Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs

AbstractPurpose. To compare gene expression profiles and drug permeability differences in Caco-2 cell culture and human duodenum. Methods. Gene expression profiles in Caco-2 cells and human duodenum were determined by GeneChip® analysis. In vivo drug permeability measurements were obtained through single-pass intestinal perfusion in human subjects, and correlated with in vitro Caco-2 transport permeability. Results. GeneChip® analysis determined that 37, 47, and 44 percent of the 12,559 gene sequences were expressed in 4-day and16-day Caco-2 cells and human duodenum, respectively. Comparing human duodenum with Caco-2 cells, more than 1000 sequences were determined to have at least a 5-fold difference in expression. There were 26, 38, and 44 percent of the 443 transporters, channels, and metabolizing enzymes detected in 4-day, 16-day Caco-2 cells, and human duodenum, respectively. More than 70 transporters and metabolizing enzymes exhibited at least a 3-fold difference. The overall coefficient of variability of the 10 human duodenal samples for all expressed sequences was 31% (range 3% to 294%) while that of the expressed transporters and metabolizing enzymes was 33% (range 3% to 87%). The in vivo / in vitro drug permeability measurements correlated well for passively absorbed drugs (R2 = 85%). The permeability correlation for carrier-mediated drugs showed 3- 35-fold higher in human above the correlation of passively absorbed drugs. The 2- 595-fold differences in gene expression levels between the Caco-2 cells and human duodenum correlated with the observed 3- 35-fold difference in permeability correlation between carrier-mediated drugs and passively absorbed drugs. Conclusions. Significant differences in gene expression levels in Caco-2 cells and human duodenum were observed. The observed differences of gene expression levels were consistent with observed differences in carrier mediated drug permeabilities. Gene expression profiling is a valuable new tool for investigating in vitro and in vivo permeability correlation.

[1]  M. Fromm,et al.  Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. , 2000, The Journal of pharmacology and experimental therapeutics.

[2]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[3]  J. R. Sportsman,et al.  Association of intestinal peptide transport with a protein related to the cadherin superfamily. , 1994, Science.

[4]  G. Amidon,et al.  Human Jejunal Permeability of Two Polar Drugs: Cimetidine and Ranitidine , 2001, Pharmaceutical Research.

[5]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  Hitoshi Sezaki,et al.  Analysis of Drug Permeation Across Caco-2 Monolayer: Implication for Predicting In Vivo Drug Absorption , 1997, Pharmaceutical Research.

[7]  R. Palmer,et al.  Cimetidine and ranitidine. Lack of effect on the pharmacokinetics of an acute ethanol dose. , 1993, Journal of clinical gastroenterology.

[8]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[9]  V. Ganapathy,et al.  Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.

[10]  G. Amidon,et al.  Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. , 2001, Journal of Pharmacology and Experimental Therapeutics.

[11]  Patrick J. Sinko,et al.  Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds , 2004, Pharmaceutical Research.

[12]  G. Amidon,et al.  Human Intestinal Permeability of Piroxicam, Propranolol, Phenylalanine, and PEG 400 Determined by Jejunal Perfusion , 1997, Pharmaceutical Research.

[13]  W. J. Irwin,et al.  Suitability of Enalapril as a Probe of the Dipeptide Transporter System: InVitro and In Vivo Studies , 1996, Pharmaceutical Research.

[14]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[15]  Shiew-Mei Huang,et al.  Effects of Structural Modifications on the Intestinal Permeability of Angiotensin II Receptor Antagonists and the Correlation of In Vitro, In Situ, and In Vivo Absorption , 1996, Pharmaceutical Research.

[16]  T. Tsuruo,et al.  The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier , 2000, Brain Research.

[17]  G. Amidon,et al.  Passive and Carrier-Mediated Intestinal Absorption Components of Two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril , 1989, Pharmaceutical Research.

[18]  S. Stavchansky,et al.  Link between drug absorption solubility and permeability measurements in Caco-2 cells. , 1998, Journal of pharmaceutical sciences.

[19]  David E. Smith,et al.  Competitive Inhibition of Glycylsarcosine Transport by Enalapril in Rabbit Renal Brush Border Membrane Vesicles: Interaction of ACE Inhibitors with High-Affinity H+/Peptide Symporter , 1999, Pharmaceutical Research.

[20]  G. Amidon,et al.  CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. , 1999, Journal of pharmaceutical sciences.

[21]  Patrick J. Sinko,et al.  Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach , 1991, Pharmaceutical Research.

[22]  G. Amidon,et al.  Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group. , 1982, Journal of pharmaceutical sciences.

[23]  Ismael J. Hidalgo,et al.  The Role of an α‐Amino Group on H+‐dependent Transepithelial Transport of Cephalosporins in Caco‐2 Cells , 1999 .

[24]  P. Augustijns,et al.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. , 1993, Biochemical and biophysical research communications.

[25]  G. Amidon,et al.  Overexpression of Human Intestinal Oligopeptide Transporter in Mammalian Cells via Adenoviral Transduction , 1998, Pharmaceutical Research.

[26]  J. Cunningham,et al.  Glucose Transporter Glut3 Is Targeted to Secretory Vesicles in Neurons and PC12 Cells* , 1999, The Journal of Biological Chemistry.

[27]  T. Kissel,et al.  Prodrug Approach for αΙΙbβ3-Peptidomimetic Antagonists to Enhance Their Transport in Monolayers of a Human Intestinal Cell Line (Caco-2): Comparison of In Vitro and In Vivo Data , 1999, Pharmaceutical Research.

[28]  G L Amidon,et al.  Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. , 2000, Journal of pharmaceutical sciences.

[29]  M. Yazdanian,et al.  Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds , 1998, Pharmaceutical Research.

[30]  Andrew Crowe,et al.  In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with Rapamycin , 1998, Pharmaceutical Research.

[31]  G. Amidon,et al.  HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. , 1996, Journal of pharmaceutical sciences.

[32]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[33]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[34]  M. Kataoka,et al.  Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[36]  G. Amidon,et al.  Characterization of the Oral Absorption of Some β-Lactams Effect of the α-Amino Side Chain Group , 1993 .

[37]  S. Chong,et al.  In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System , 2004, Pharmaceutical Research.

[38]  D. Jack,et al.  CIMETIDINE AND RANITIDINE , 1982, The Lancet.